Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    Hereditary Breast and Ovarian Cancer | United States, Georgia
Show Display Options
Rank Status Study
1 Active, not recruiting Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacological study

Indicates status has not been verified in more than two years